医薬品連続生産の北米市場2020-2237

◆英語タイトル:NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET FORECAST 2020-2028
◆商品コード:INK20MY288
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:111
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:北米
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGS The North America pharmaceutical continuous manufacturing market is estimated to project a CAGR of 8.25% during the forecast period of 2020-2028. The presence of a large number of pharmaceutical and biopharmaceutical companies, wide accessibility of advanced pharmaceutical continuous manufacturing systems, and availability of trained professionals to handle complex manufacturing equipment are the factors impacting the market growth.

MARKET INSIGHTS
In order to study the North America pharmaceutical continuous manufacturing market further, the region is segmented into the United States and Canada. In Canada, an association of pharmaceutical companies for R&D was founded in 1914 and represented more than 50 brand name companies, the majority being subsidiaries of foreign multinationals. The CGPA has ten member companies, and the non-Canadian corporations own more than half of it. The pharmaceutical industry is modifying itself according to new pressures, which include patent cliff, an unprecedented expiration of patents for many blockbuster drugs, and continuing cost control measures from both public and private payers. These external market challenges, along with an increasingly competitive global corporate effective for investment and improved R&D return, will continue to reform their operations. The Canadian pharmaceutical industry is highly impacted by the changes occurring at the global level and are inciting new challenges and opportunities. Further, according to the Canadian government, the pharmaceutical industry of Canada is an agglomeration of multinationals and local companies. The branded pharmaceuticals MNEs represent the largest portion of R&D investment and drug sales. They traditionally develop and market new patented products, and are mostly foreign multinationals with subsidiaries in Canada.

COMPETITIVE INSIGHTS
Pfizer Inc, Eli Lilly, and Company, GEA Group, Thermo Fisher, Munson Machinery Company Inc, etc. are some of the renowned companies operating in the market.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. INCREASED ADOPTION OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
3.2.2. RISING GOVERNMENTS INITIATIVES FOR THE ADOPTION OF CONTINUOUS MANUFACTURING SYSTEMS
3.3. KEY RESTRAINTS
3.3.1. INCREASING CUSTOMER ANTICIPATIONS
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. REGULATORY FRAMEWORK
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. KEY INVESTMENT INSIGHTS
5. MARKET BY PRODUCT
5.1. INTEGRATED CONTINUOUS SYSTEM
5.2. SEMI-CONTINUOUS SYSTEM
5.3. CONTROL & SOFTWARE
6. MARKET BY APPLICATION
6.1. FINAL DRUG PRODUCT MANUFACTURING
6.2. API MANUFACTURING
7. MARKET BY END-USER
7.1. PHARMACEUTICAL COMPANIES
7.2. CONTRACT MANUFACTURING ORGANIZATIONS
7.3. OTHER END-USERS
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. THE UNITED STATES
8.1.2. CANADA
9. COMPANY PROFILES
9.1. COPERION GMBH
9.2. ELI LILLY & COMPANY
9.3. GEA GROUP AG
9.4. GEBRUDER LODIGE MASCHINENBAU GMBH
9.5. GLATT GMBH
9.6. HOSOKAWA MICRON CORPORATION
9.7. KORSCH AG
9.8. L.B. BOHLE MASCHINEN + VERFAHREN GMBH
9.9. MUNSON MACHINERY COMPANY
9.10. PFIZER INC
9.11. SIEMENS HEALTHINEERS
9.12. SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
9.13. THERMO FISHER SCIENTIFIC INC



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[医薬品連続生産の北米市場2020-2237]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆